Compare AbCellera Biologics Inc (ABCL) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs ProShares UltraPro QQQ ETF — how do they compare? AbCellera Biologics Inc trades at $10.31 (market cap $2.99B), while ProShares UltraPro QQQ ETF trades at $74.42. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | TQQQ | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $9.76 | $87.22 |
52-Week Low | $2.78 | $37.89 |
Enterprise Value | $2.58B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
TQQQ trades at $74.61, up 1.12% with a bullish technical signal from moving averages. The leveraged ETF benefits from strong Nasdaq-100 performance and AI-driven tech momentum. Recent institutional buying by Bay Colony Advisory Group and positive earnings from hyperscalers support current levels. However, the RSI at 74 suggests potential overbought conditions near key resistance at $75.
Outlook remains positive given tech sector strength, but volatility decay and leverage risks require careful position sizing. The ETF's structural costs compound daily, making it better suited for tactical rather than long-term holdings. Current momentum favors continued upside if tech earnings maintain strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
